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Abstract
Background—To investigate the inhibitory role of pterostilbene in pancreatic cancer, we 
conducted a genomic analysis of pterostilbene-treated pancreatic cancer cells. We also 
investigated the effect of pterostilbene upon the carcinogenic markers, manganese superoxide 
dismutase, cytochrome C, Smac/DIABLO, and STAT3 phosphorylation in vitro. The 
antiproliferative effects of pterostilbene were further evaluated in an in vivo model.
Methods—Pancreatic cancer cells were treated with pterostilbene and evaluated with DNA 
microarray analysis. Pterostilbenetreated cells were analyzed for cytochrome C, Smac/DIABLO, 
manganese superoxide dismutase (MnSOD)/antioxidant activity, and STAT3 phosphorylation 
using ELISA. Data were statistically analyzed using ANOVA. Pterostilbene was then 
administered to nude mice for 8 weeks, and tumor growth rates were recorded and statistically 
analyzed.
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Results—Microarray analysis of pterostilbene-treated cells revealed upregulation of pro-
apoptosis genes. In vitro, pterostilbene treatment altered levels of phosphorylated STAT3, 
MnSOD/antioxidant activity, cytochrome C, and Smac/DIABLO. In nude mice, oral pterostilbene 
inhibited tumor growth rates.
Conclusion—Pterostilbene alters gene expression in pancreatic cancer and increases the 
antiproliferative markers cytochrome C, Smac/DIABLO, and MnSOD/antioxidant activity. It was 
also shown to inhibit phosphorylated STAT3, a marker of accelerated tumorigenesis, and decrease 
pancreatic tumor growth in vivo. Further studies are warranted to elucidate the effects of 
pterostilbene in humans.
Keywords
Pancreatic cancer; Pterostilbene; Apoptosis
Introduction
Pancreatic cancer is the fourth leading cause of cancerrelated death in the USA with an 
overall estimated 5-year survival of less than 5 %.1,2 Poor prognosis in pancreatic cancer is 
attributed to late stage diagnosis, local tumor aggression, and high rates of 
chemoresistance.1,2 Surgical resection of pancreatic cancer can be curative; however, only 
15–20 % of pancreatic cancer patients are surgical candidates.2 Chemotherapeutic options 
include gemcitabine, which is the only approved chemotherapeutic agent for treatment of 
pancreatic cancer, with a dismal response rate of 5 %.1,2 Recently, FOLFIRINOX has been 
shown to be efficacious for metastatic pancreatic cancer, but with significant side effects.3 
Therefore, the quest for novel treatment options in the management of pancreatic cancer is 
of monumental significance.
We have previously demonstrated that pterostilbene (3, 5-dimethoxy-4-hydroxystilbene), an 
antioxidant found in blueberries, reduces proliferation in pancreatic cancer in vitro through 
mitochondrial membrane depolarization, caspase 3/7 activation, and cell cycle arrest.1,4 To 
further elucidate the mechanism of pterostilbene, we conducted a microarray genomic 
analysis of pterostilbene-treated pancreatic cancer cells to identify upregulated and 
downregulated genes. Manganese superoxide dismutase (MnSOD), an antioxidant located in 
the mitochondria, was found to be significantly upregulated by pterostilbene in the genomic 
microarray analysis. Hence, we further investigated the effect of pterostilbene upon this 
enzyme.
Interestingly, studies have shown that pancreatic cancer cells have decreased expression of 
MnSOD as compared to normal cells. MnSOD overexpression studies in pancreatic cancer 
show that increased MnSOD activity correlates with decreased rates of tumor growth.5-8 We 
hypothesized that pterostilbene would increase MnSOD enzymatic activity in a dose-
dependent manner and decrease intracellular oxidative stress.
Additionally, we investigated the effect of pterostilbene upon two mitochondrial markers of 
intrinsic apoptosis, cytochrome C and second mitochondrially derived activator of caspase 
(Smac/DIABLO). During apoptosis and following the loss of outer mitochondrial membrane 
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polarization, both cytochrome C and Smac/DIABLO are released from the intermembrane 
mitochondrial space into the cytosol.4 Upon its release into the cytosol, cytochrome C 
directly induces caspase activation leading to programmed cell death. Smac/DIABLO, 
however, indirectly induces apoptosis by blocking inhibitor of apoptosis proteins, which in 
turn allows apoptosis to proceed.4 In addition, in vivo pancreatic tumor models show that 
Smac mimetic proteins induce tumor regression and prolong survival in mouse models both 
alone and in combination with gemcitabine, making it a potential therapeutic target of 
pterostilbene.9 Based on our genomic analysis, we hypothesized that pterostilbene would 
increase cytosolic levels of cytochrome C and Smac/DIABLO in a dose-dependent fashion 
further signifying a mitochondrially derived mechanism of cell death.
We also investigated the effect of pterostilbene upon STAT3 phosphorylation, a marker of 
the constitutively active Janus kinase/signal transducer and activator of transcription-3 
(JAK/STAT3) pathway, which is associated with pancreatic tumorigenesis, decreased 
apoptosis, and enhanced metastatic potential.10-12 We hypothesized that pterostilbene 
treatment would decrease phosphorylated STAT3, thereby indicating downregulation of the 
JAK/STAT3 pathway. The final component of our study was a mouse xenograft model used 
to determine whether the inhibitory effects of pterostilbene were applicable to human 
pancreatic tumors in vivo. We hypothesized that orally administered pterostilbene would 
inhibit pancreatic adenocarcinoma growth in a nude mouse model.
Materials and Methods
Pterostilbene
Pterostilbene (3, 5-dimethoxy-4-hydroxystilbene) was purchased from Sigma-Aldrich (St. 
Louis, MO, USA) and reconstituted into dimethyl sulfoxide (DMSO) solution (Sigma-
Aldrich, St. Louis, MO, USA). Experimental pterostilbene concentrations were formulated 
using sterile media dilutions.
Cell Culture
MIA PaCa-2 and PANC-1 cells were purchased from the American Type Culture Collection 
(Manassas, VA, USA). Cells were maintained as monolayers in T-25 flasks in Dulbecco’s 
modification eagle’s medium (Mediatech, Inc., Herndon, VA, USA) supplemented with 10 
% fetal bovine serum (HyClone, Logan, UT, USA) and 1 % penicillin/streptomycin 
(Mediatech, Inc.). Flasks were kept at 37 °C in a water-jacketed 5 % CO2 incubator (Fisher 
Scientific, Houston, TX, USA). Cells were harvested from culture monolayers at 80–90 % 
confluency and rinsed with sterile phosphate-buffered saline (PBS; Mediatech, Inc.). Live 
cells were detached using 0.25 % trypsin in 0.1 % EDTA (Mediatech, Inc.), centrifuged at 
1,000 rpm for 5 min, and resuspended in PBS to obtain specific concentrations for 
cytochrome C, Smac/DIABLO, STAT3, and MnSOD/antioxidant assays.
RNA Preparation and Microarray Analysis
MIA PaCa-2 cells were treated with 50 μM pterostilbene for 3, 6, 9, and 12 h. A final cell 
concentration of 6×106 per 200 μL was obtained, and RNA isolation was performed by 
direct extraction of adherent cells from the tissue culture plate at 70 % confluency using the 
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RNeasy Mini Kit (Qiagen, Valencia, CA, USA). The resulting RNA was quantified using 
the Nanodrop spectrophotometer and analyzed for integrity using the Agilent Bioanalyzer 
2100. RNA amplification, fragmentation, and labeling were performed using the Ovation V2 
and Encore reagents by NuGEN technologies.13,14
Microarray Data Analysis
Hybridization mixes were prepared using 4 μg of the final amplified sample and hybridized 
to the Human Genome U133 2.0 Plus GeneChip array (Affymetrix, Santa Clara, CA, USA) 
as per manufacturer’s recommendations for 16 h at 45 °C at 60 rpm, double stained with 
streptavidin-PE using the Affymetrix 450 fluidics station, and scanned with the Affymetrix 
3000-G7 scanner. Data analysis was performed at the university Bioinformatic Core Facility 
using Bioconductor Software and analyzed using Robust Multichip Analysis.
Cytochrome C ELISA
MIA PaCa-2 and PANC-1 cells were plated at 106 cells per well into 100-mm culture dishes 
and allowed to adhere for 24 h. Cells were incubated with a DMSO control or 25-, 50-, and 
75-μM concentrations of pterostilbene for 24 h. Cell lysates were prepared using a digitonin 
cell permeabilization assay protocol followed by centrifugation at 1,000×g for 5 min to 
obtain cytosolic and mitochondrial fractions. Cytosolic fractions were then evaluated for 
cytochrome C according to the ELISA protocol (Enzo Life Sciences, Plymouth Meeting, 
PA, USA). Protein analysis was performed, and cytochrome C was measured and expressed 
in picograms per milligram.
Smac/DIABLO ELISA
MIA PaCa-2 and PANC-1 cells were plated at 106 cells per well into 100-mm culture dishes 
and allowed to adhere for 24 h. Cells were incubated with a DMSO control or 25-, 50-, and 
75-μM concentrations of pterostilbene for 24 h. Cell lysates were prepared using a digitonin 
cell permeabilization assay protocol followed by centrifugation at 1,000×g for 5 min to 
obtain cytosolic and mitochondrial fractions. Cytosolic fractions were then evaluated for 
Smac/DIABLO using a sandwich ELISA protocol (R&D Systems, Minneapolis, MN, USA). 
Protein analysis was performed, and Smac/DIABLO was measured and expressed in 
picograms per milligram.
MnSOD Activity
MIA PaCa-2 and PANC-1 cells were plated at 106 cells per well into 100-mm culture dishes 
and allowed to adhere for 24 h. Cells were incubated with a DMSO control or 25- and 50-
μM concentrations of pterostilbene for 48 h to optimize enzymatic activity with minimal cell 
cytotoxicity. Cells were lysed with Triton X-100 cell lysis buffer and centrifuged at 
12,000×g for 5 min. Supernatants were assayed for MnSOD activity after addition of 2 mM 
cyanide to block Cu/Zn-SOD activity (Cell Technology Inc., Mountain View, CA, USA). A 
protein analysis was performed, and MnSOD enzymatic activity was measured and 
expressed in picograms per milligram.
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Antioxidant Activity
Detection of malondialdehyde (MDA), a by-product of lipid peroxidation, was used as a 
marker of antioxidant activity. MIA PaCa-2 and PANC-1 cells were plated at 3×105 cells 
per well into six-well plates and allowed to adhere for 24 h. Cells were then incubated with 
DMSO and 25-, 50-, and 75-μM concentrations of pterostilbene for 24 h. Cells were rinsed 
with media and incubated with 500 μM hydrogen peroxide for 1 h. Cell lysates were 
prepared according to the Oxiselect MDA Adduct ELISA protocol (Cell Biolabs, San Diego, 
CA).
STAT3 ELISA
STAT3 phosphorylation was used as a marker of JAK/STAT3 activation. MIA PaCa-2 and 
PANC-1 cells were plated in 100-mm dishes at 106 cells per dish and allowed to adhere 
overnight. Both cell lines were treated with 25, 50, and 75 μM of pterostilbene for 24 and 48 
h. Cells were lysed, and analysis of STAT3 phosphorylation was performed using the 
pSTAT3 ELISA (Invitrogen, Carlsbad, CA, USA). Quantitative values of STAT3 
phosphorylation were calculated based on the standard curve and adjusted for protein 
sample content using a standard protein assay.
Statistical Analysis
GraphPad Prism software using ANOVA and Tukey post hoc analysis was used to analyze 
experimental data.
Tumor Volume
Animals—The nude mice protocol was reviewed and approved by the University of 
Vermont Institutional Animal Care and Use Committee. Forty Nu/Nu female mice were 
obtained from Charles River Laboratories, Canada, and housed in the health sciences 
research facility at the University of Vermont. The mice were allowed to acclimate for a 
period of 1 week before the start of the study. The mice were housed under barrier 
conditions in Lab Products Micro-Isolator Ventilated Racks and kept on a 12-h day/night 
cycle with constant temperature and environmental control (70–72°F, 30–70 % humidity).
Oral Pterostilbene Dosing—Pterostilbene concentrations were prepared by adding 
pterostilbene into DMSO solution and autoclaved water. Animals received oral pterostilbene 
or a DMSO control diet. Oral dosing of pterostilbene was grouped into three categories of 
100, 500, and 1 mg/kg/day, via oral gavage using a stainless steel gavage needle attached to 
a sterile tuberculin syringe.
Tumor Inoculation—Mice were anesthetized with 3 % isofluorane, purchased from the 
Veterinary Department at the University of Vermont and supplied by Webster Veterinary 
Supply (Sterling, MA), while in a laminar flow hood with appropriate sterile precautions and 
conditions. After ensuring that proper anesthesia was achieved, the right flank of each 
animal was prepped in the usual sterile fashion, and 6×106 MIA PaCa-2 cells with PBS, 
total volume of 200 μL, was injected into the subcutaneous tissue. The mice were monitored 
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for adverse reactions and allowed to recover for 1 week after the inoculation before 
undergoing tumor volume assessment.
Tumor Measurement/Animal Weight—Tumor volume was measured in cubic 
millimeters three times weekly using the formula TV 0[L ×(W2)]/2. The smallest tumor 
volume acceptable for initiation of treatment was 150 mm3. The length (caudal–cranial axis) 
and width (ventral–dorsal axis) were measured using digital display calipers (Fisher 
Scientific, Houston, TX, USA). If variations in tumor dimensions were observed, repeat 
measurements were performed, and the average was recorded. The mice were weighed three 
times weekly on a Mettler PM3000 digital scale (Hightstown, NJ) to monitor potential 
undue weight loss of the animals and to observe any interactions between tumor burden and 
overall health. If multiple tumors developed on one mouse, the combined total volume of the 
tumors was used as the recorded tumor volume. Animals underwent a total of 8 weeks of 
oral gavage with the appropriate concentration solution before they were eligible for 
removal from the protocol via euthanasia. Mice that completed 8 weeks of treatment were 
euthanized, and tumors were procured and immediately stored in formalin.
Statistical Analysis—In conjunction with the Medical Biostatistics Department at the 
University of Vermont, a standard exponential growth model was constructed. The 
following formula was used: V0P0×Exp (P1 × T), where P00tumor volume at T00 and 
P10growth rate parameter since the rate of change in the tumor volume is dV/dT0P1 × V. 
The parameter estimates for P0 and P1 were obtained for each group, along with the 95 % 
confidence intervals, using a nonlinear regression approach.
Tumor Histology
Xenograft tumors were sectioned by the Pathology Department at the University of 
Vermont/Fletcher Allen Health Care. Tumors were stained with hematoxylin and eosin 
(H&E) for histologic evaluation and examined under light microscopy. Morphologic 
features were compared between pterostilbene treatment and control groups.
Results
Pterostilbene Genomic Profile
After 12 h, the samples demonstrated numerous upregulated (greater than fourfold) and 
downregulated (greater than threefold) genes (Table 1). Upregulated genes included heme 
oxygenase, DNA-damage-inducible transcript 3 (DDIT-3), growth differentiation factor 15, 
and mitochondrial superoxide dismutase. Downregulated genes included beta 8 integrin, 
cytochrome P450, and dehydrogenase/reductase (SDR Family).
Pterostilbene Increases Cytosolic Cytochrome C
In both MIA PaCa-2 and PANC-1 cells, pterostilbene treatment produced an increase in 
cytosolic cytochrome C levels. In the MIA PaCa-2 cell line, 25 and 50 μM pterostilbene 
increased cytosolic levels of cytochrome C (p<0.001), and in PANC-1 cells, pterostilbene 
treatment produced a doserelated increase in cytosolic cytochrome C levels at concentrations 
of 25 μM (p<0.001), 50 μM (p<0.01), and 75 μM (p<0.05) (Fig. 1).
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Pterostilbene Increases Cytosolic Smac/DIABLO
In both MIA PaCa-2 and PANC-1 cells, pterostilbene treatment produced an increase in 
cytosolic Smac/DIABLO. In the MIA PaCa-2 cell line, 75 μM pterostilbene increased (p< 
0.001) Smac/DIABLO. In PANC-1 cells, pterostilbene treatment increased cytosolic Smac/
DIABLO at concentrations of 25 μM (p<0.01) and 75 μM (p<0.001) (Fig. 2).
Pterostilbene Increases MnSOD Activity
Pterostilbene treatment upregulated MnSOD activity in MIA PaCa-2 and PANC-1 cells at 
concentrations of 25 and 50 μM (p<0.01), demonstrating pterostilbene’s effect upon 
inducible mitochondrial enzymatic activity (Fig. 3).
Pterostilbene Decreases Oxidative Stress
Pterostilbene treatment for 24 h reduced the amount of MDA protein adducts detected after 
treatment with hydrogen peroxide, indicating an increase in antioxidant activity (Fig. 4). In 
the MIA PaCa-2 cell line, all concentrations of pterostilbene decreased MDA protein 
adducts (p<0.05, p<0.01); however, in PANC-1, the effect reached statistical significance 
only with the 75-μM dose of pterostilbene (p<0.01).
Pterostilbene Inhibits Constitutive STAT3 Phosphorylation
Treatment with 25, 50, and 75 μM of pterostilbene produced a dose- and time-dependent 
decrease in constitutive STAT3 phosphorylation at 24- and 48-h time points in both MIA 
PaCa-2 (p<0.05, p<0.01) and PANC-1 cells (p<0.001) (Fig. 5).
Oral Pterostilbene Decreases Pancreatic Tumor Volume in Mice
There was a 100 % survival rate amongst mice receiving pterostilbene treatment and a 66 % 
survival rate in the control group (p<0.01). The calculated growth rate parameter for the 
control group was 0.0522. For pterostilbene-fed mice, the calculated growth rate parameters 
were 0.0260 for the 100-μg/kg/day group, 0.0264 for the 500-μg/kg/day group, and 0.0371 
for the 1-mg/kg/day group. Oral administration of pterostilbene significantly inhibited tumor 
growth in the 100- and 500-μg/kg/day groups versus controls, based on the calculated 95 % 
confidence interval (Table 2).
In Vivo Tumor Histology
Histologic evaluation of the mouse tumors found poorly differentiated adenocarcinoma 
consisting of markedly pleomorphic round to ovoid cells with abundant eosinophilic 
cytoplasm and eccentric nuclei (Fig. 6b and d). The nuclei had vesicular chromatin and 
prominent nucleoli. Glandular formation was not seen as the tumors had a solid nested 
pattern with pushing borders. Rare foci of skeletal muscle invasion were evident in the 
control tumors and the 500-μg/kg treated tumors. Perineural invasion, a typical finding in 
pancreatic adenocarcinoma specimens, was seen at the edge of the 500-μg/kg treated tumors. 
The morphologic features of the tumors were similar throughout the treatment groups and 
did not vary significantly from the control tumors (Fig. 6a–d). All tumors showed prominent 
central necrosis comprising 60–80 % of the tissue, which did not significantly differ among 
treatment groups.
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Discussion
Resveratrol has been considered an important component of the Mediterranean diet as it is 
found in red wine. Unfortunately, a liter bottle of red wine contains an average of 3 mg of 
resveratrol, which has only an approximate 30 % bioavailability.15 Pterostilbene, an analog 
of resveratrol (trans-3, 5-dimethoxy-4-hydroxystilbene), is a phenylpropanoid-derived plant 
compound found in blueberries, several types of grapes, and tree wood.16 In nature, 
pterostilbene acts as a phylotaxin and is significantly increased during times of plant stress 
in response to microbial attack, ultraviolet light, and irradiation mainly as a protective 
mechanism.17 Additionally, pterostilbene has nearly three times the bioavailability of 
resveratrol.18
First, we have demonstrated in the pancreatic cancer cell line MIA PaCa-2 that pterostilbene 
causes alteration of antiapoptosis and pro-apoptosis gene expression using DNA microarray 
analysis, its net effect supporting pro-apoptosis. Our results show for the first time that 
pterostilbene significantly upregulates genomic expression of DDIT-3, growth 
differentiation factor 15, also known as macrophage inhibitory cytokine 1, and MnSOD, 
which are all associated with induction of pancreatic cancer cell death.5-8,19,20 Pterostilbene 
also significantly upregulated heme oxygenase-1 (HO-1), an inducible stress-response 
protein. Enhanced HO-1 expression is thought to increase resistance to cell death; however, 
in pancreatic cancer cells, HO-1 is also upregulated in response to radiation, gemcitabine, 
and oxidative stress suggesting an anticancer effect.21
Based on the results of the genomic analysis, we performed a MnSOD enzymatic activity 
assay in two pterostilbene-treated pancreatic cancer cell lines to determine if increased 
genomic expression of MnSOD translated into increased mitochondrial enzymatic activity. 
MnSOD was chosen as a gene to further investigate because numerous studies demonstrate a 
significant relationship between MnSOD expression and cancer growth. The results confirm 
that pterostilbene’s upregulation of MnSOD at the genomic level also translates into 
increased enzymatic activity, indicating that the mitochondrially derived enzyme plays a 
significant role in promoting pterostilbene’s effect on pancreatic cancer cells. Likewise, 
pterostilbene treatment decreased MDA adduct production indicating increased antioxidant 
activity. In addition to upregulating MnSOD activity, pterostilbene also significantly 
increased cytosolic levels of the apoptotic markers cytochrome C and Smac/DIABLO which 
may suggest mitochondrial release of both proteins from the inner mitochondrial membrane. 
Based on these findings, we may infer that pterostilbene promotes cell death and decreased 
proliferation in pancreatic cancer in vitro through a mitochondrially derived mechanism. 
Moreover, we have shown that oral pterostilbene administration in an in vivo model inhibits 
pancreatic cancer growth, which further supports the results obtained in our in vitro model. 
In our present study, in vitro and in vivo pterostilbene doses were determined based on prior 
pharmacokinetic studies in rats; however, the exact relationship between in vitro and in vivo 
dosing is currently unknown.
In conclusion, pancreatic cancer is associated with high rates of chemoresistance and low 
chances of 5-year survival.1,2 We have now shown that the natural dietary compound 
pterostilbene inhibits pancreatic cancer both in vitro and in vivo. Further studies are needed 
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to elucidate the chemotherapeutic and chemo-preventative potential of pterostilbene in the 
treatment of pancreatic cancer in preclinical trials.
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Fig. 1. 
MIA PaCa-2 cells treated with 25 and 50 μM pterostilbene had an increase in cytosolic 
cytochrome C when compared to control (***p< 0.001). However, 75 μM decreased 
cytosolic cytochrome C. PANC-1 cells treated with 25, 50, and 75 μM showed a dose-
related increase in cytosolic cytochrome C release when compared to control (***p<0.001; 
**p<0.01; *p<0.05)
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Fig. 2. 
MIA PaCa-2 cells treated with 75 μM pterostilbene had an increase in Smac/DIABLO when 
compared to control (***p<0.001). PANC-1 cells treated with 25 and 75 μM pterostilbene 
showed a dose-related increase in Smac/DIABLO when compared to control (***p<0.001; 
**p<0.01)
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Fig. 3. 
MIA PaCa-2 and PANC-1 cells treated with 25 and 50 μM pterostilbene had a significant 
increase in MnSOD enzymatic activity when compared to controls (**p<0.01)
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Fig. 4. 
In MIA PaCa-2 cells, pterostilbene decreased MDA adducts (*p<0.05; **p<0.01). In 
PANC-1, MDA protein adducts were decreased with 75 μM pterostilbene (**p<0.01)
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Fig. 5. 
Inhibition of phosphorylated STAT3 was seen in both MIA PaCa-2 (*p< 0.05; **p<0.01; 
***p<0.001) and PANC-1 cells (*** p<0.001) with pterostilbene treatment
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Fig. 6. 
a Control ×100, viable tumor in upper left, necrosis in lower right. b Treatment group ×100, 
viable tumor in upper left, necrosis in lower right. The volume of necrosis was 
approximately the same for all treatment doses and the control. c Control ×400, cell 
morphology and cytology. d Treatment group ×400, cell morphology and cytology were 
similar for all treatment doses and the control
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Table 1
List of genes up- or downregulated by pterostilbene by at least threefold with associated p values
Gene name Ratio p value Identifier
Upregulated
Heme oxygenase (decycling) 1 16.96 0.00444 NM_002133
DNA-damage-inducible transcript 3 6.3 0.00622 BC003637
Chemokine (C-X-C motif) ligand 3 6.08 0.03221 NM_002090
Growth differentiation factor 15 4.66 0.00273 AF003934
Superoxide dismutase 2, mitochondrial 4.53 0.03353 AL050388
Heat shock 70 kDa protein 9 (mortalin) 4.33 0.00124 AK023317
Seryl-tRNA synthetase 4.33 0.00251 BF111108
Fucosyltransferase 1 4.05 0.00313 NM_000148
Integrin, beta 8 4.03 0.01345 BF513121
Heterogeneous nuclear ribonucleoprotein 4.01 0.01924 AL713781
Downregulated
Zinc finger protein 488 4.32 0.04088 AIO56483
Integrin, beta 8 4.03 0.01345 BF513121
Cytochrome P450, family 1, subfamily A 3.58 0.00029 NM_000499
Dehydrogenase/reductase (SDR family) 3.15 0.01714 BC015030
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